Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the results from a large retrospective analysis, which aimed to compare the outcomes of patients with light chain (AL) amyloidosis in two different time periods, before and after bortezomib-based therapy became widely used. Dr Kastritis highlights some important findings, including the need for earlier diagnosis of AL amyloidosis to improve patient outcome, the effects of bortezomib and second-line therapies such as lenalidomide, and the overall survival figures observed in this patient cohort throughout this time period. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.

свернуть